Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
Public ClinicalTrials.gov record NCT00095381. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced T-cell leukemia. Patients will receive an infusion of BCX-1777 on days 1-5. Treatment may be repeated every week for up to six courses. Patients are not required to be hospitalized for the administration of BCX-1777. Some patients may continue to receive an infusion of BCX-1777 twice a week for 6 weeks.
Study identification
- NCT ID
- NCT00095381
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2004 (Type not available)
- Primary completion
- Mar 2007 (Actual)
- Completion
- Dec 2007 (Actual)
- Last update posted
- Jan 19, 2012
2004 – 2007
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90024 | — |
| Not listed | Palo Alto | California | 94304 | — |
| Not listed | Denver | Colorado | 80262 | — |
| Not listed | Gainesville | Florida | 32611 | — |
| Not listed | Lecanto | Florida | 34461 | — |
| Not listed | Atlanta | Georgia | 30322 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Kansas City | Kansas | 66160 | — |
| Not listed | New Orleans | Louisiana | 70118 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Rolla | Missouri | 65401 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Omaha | Nebraska | 68198 | — |
| Not listed | Hackensack | New Jersey | 07601 | — |
| Weil Medical College of Cornell University | New York | New York | 10021 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | Syracuse | New York | 13210 | — |
| Not listed | The Bronx | New York | 10467 | — |
| Not listed | Spartanburg | South Carolina | 29303 | — |
| Not listed | Austin | Texas | 78701 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Abingdon | Virginia | 24211 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00095381, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2012 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00095381 live on ClinicalTrials.gov.